+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Biosimilar Insulin Glargine & Lispro Market, By End User (Type 1 Diabetes and Type 2 Diabetes),By Country (Germany, United Kingdom, France, Italy, Spain, Russia, Turkey, Poland, The Netherlands, Austria & Rest of Europe), Competition, Forecast & Opportunities, 2024

  • ID: 4969007
  • Report
  • January 2020
  • Region: United Kingdom, Europe, Germany, Austria, France, Italy, Netherlands, Poland, Russia, Spain, Turkey
  • 86 pages
  • TechSci Research
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The European Biosimilar Insulin Glargine and Lispro Market is Projected to Reach $ 1.9 Billion By 2024.

FEATURED COMPANIES

  • Biocon Limited
  • Eli Lily and Company
  • Geropharm LLC
  • Merck & Co.
  • Novo Nordisk A/S
  • Sandoz
  • MORE
The European Biosimilar Insulin Glargine and Lispro Market is projected to reach $ 1.9 billion by 2024 owing to rising levels of obesity, growing expenditure on healthcare and increasing adoption of sedentary lifestyle. United Kingdom ranks among the top 5 countries with the highest rate of Type 1 diabetes in children. Therefore, in order to address rising number of diabetes patients and insulin users in the region, more and more manufacturers are trying to market biosimilar insulin which is anticipated to drive the growth of biosimilar insulin glargine and lispro market in the forthcoming years. The insulin analogue retains its glucose lowering property for 24 hours with just one injection. Due to this property, the insulin analogue is preferred for maintaining the basal insulin level throughout the day, thereby aiding the market growth. Growing concern regarding the cost of insulin treatment is surging the demand for biosimilar insulin glargine and lispro that have the potential to reduce diabetes treatment costs, which is anticipated to boost the growth of market in the next 5 years. Moreover, ageing population and changing eating habits are further giving healthy push to the European Biosimilar Insulin Glargine and Lispro Market.

On the basis of end-users, the biosimilar insulin glargine and lispro market is bifurcated into Type 1 Diabetes and Type 2 Diabetes. Among them, Type 1 Diabetes dominated the market with the largest market share until 2018 and is anticipated to maintain its position during the forecast period as well. The reason being, Type 1 diabetes is categorized as an autoimmune disease, therefore the body doesn’t produce any insulin. The only way to treat this disorder is getting oneself injected with insulin and getting the blood glucose levels regulated. Thereby, treatment of Type 1 diabetes generates maximum demand for insulin glargine and lispro in the region. With the higher adoption of sedentary lifestyle, especially in the growing economies people are facing difficulty in controlling Type 2 diabetes. Therefore, the utilization of biosimilar insulin glargine and lispro to treat Type 2 diabetes is expected to witness some growth during the forecast period.

Some of the players in the European Biosimilar Insulin Glargine and Lispro Market are Sanofi, Eli Lilly-Boehringer Ingelheim, Mylan-Biocon, Geropharm, Novo Nordisk, Sandoz-Gan Lee, etc. The key players in the market are using strategies such as launch of new products, mergers and acquisitions to increase their customer base and expand their share in the market.

Years considered for this report:
Historical Years: 2014-2017
Base Year: 2018
Estimated Year: 2019
Forecast Period: 2020–2024

Objective of the Study:
  • To analyze and forecast the market size of the European Biosimilar Insulin Glargine and Lispro Market.
  • To forecast the European Biosimilar Insulin Glargine and Lispro Market based on end-user, and regional distribution.
  • To identify drivers and challenges for the European Biosimilar Insulin Glargine and Lispro Market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the European Biosimilar Insulin Glargine and Lispro Market.
  • To conduct the pricing analysis for the European Biosimilar Insulin Glargine and Lispro Market.
  • To identify and analyze the profile of leading players operating in the European Biosimilar Insulin Glargine and Lispro Market.
Both primary as well as exhaustive secondary research were performed for this study. Initially, a list of biosimilar insulin glargine and lispro manufacturers across the region. Subsequently, primary research surveys were conducted with the identified companies were conducted. While interviewing, the respondents were also enquired about their competitors. Through this technique, the suppliers which could not be identified due to the limitations of secondary research could be included. The product types, application types and presence of all major biosimilar insulin glargine and lispro manufacturers across the region.

The European Biosimilar Insulin Glargine and Lispro Market size was calculated by using a bottom-up approach, where data for various end-user industries and its application across various product types were recorded and forecast for the future years. These values were sourced from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Target Audience:
  • Biosimilar insulin glargine and lispro manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to biosimilar insulin glargine and lispro market
  • Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as product manufacturers and partners, end-users etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.

Report Scope:

In this report, the European Biosimilar Insulin Glargine and Lispro Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By End-User:
  • Type 1 Diabetes
  • Type 2 Diabetes
Market, by Country:
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Russia
  • Turkey
  • Poland
  • The Netherlands
  • Austria
  • Rest of Europe
Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in biosimilar insulin glargine & lispro market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

Profit Margin Analysis in case of direct and indirect sales channel.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biocon Limited
  • Eli Lily and Company
  • Geropharm LLC
  • Merck & Co.
  • Novo Nordisk A/S
  • Sandoz
  • MORE
1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer
4.1. Brand Awareness
4.2. Factors Influencing Purchase Decision
4.3. Unmet Needs & Challenges

5. Global Biosimilar Insulin Market Overview

6. Europe Biosimilar Insulin Glargine & Lispro Market Outlook
6.1. Market Size & Forecast, (2014-2024)
6.1.1. By Value (USD Million) & Volume (Million Units)
6.2. Market Share & Forecast (2014-2024)
6.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.2.2. By Country (United Kingdom, Germany, France, Spain, Italy, Russia, Netherlands, Poland, Turkey & Rest of Europe)
6.2.3. By Company (2018)
6.3. Market Attractiveness Index
6.4. Competition Outlook
6.4.1. Major Biosimilar Insulin Glargine & Lispro Suppliers with products registered and sold
6.5. Country Analysis
6.5.1. Germany Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.1.1. Market Size & Forecast
6.5.1.1.1. By Value & Volume
6.5.1.2. Market Share & Forecast
6.5.1.2.1. By End User
6.5.2. United Kingdom Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.2.1. Market Size & Forecast
6.5.2.1.1. By Value & Volume
6.5.2.2. Market Share & Forecast
6.5.2.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.3. France Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.3.1. Market Size & Forecast
6.5.3.1.1. By Value & Volume
6.5.3.2. Market Share & Forecast
6.5.3.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.4. Italy Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.4.1. Market Size & Forecast
6.5.4.1.1. By Value & Volume
6.5.4.2. Market Share & Forecast
6.5.4.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.5. Spain Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.5.1. Market Size & Forecast
6.5.5.1.1. By Value & Volume
6.5.5.2. Market Share & Forecast
6.5.5.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.6. Russia Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.6.1. Market Size & Forecast
6.5.6.1.1. By Value & Volume
6.5.6.2. Market Share & Forecast
6.5.6.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.7. Turkey Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.7.1. Market Size & Forecast
6.5.7.1.1. By Value & Volume
6.5.7.2. Market Share & Forecast
6.5.7.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.8. Poland Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.8.1. Market Size & Forecast
6.5.8.1.1. By Value & Volume
6.5.8.2. Market Share & Forecast
6.5.8.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.9. The Netherlands Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.9.1. Market Size & Forecast
6.5.9.1.1. By Value & Volume
6.5.9.2. Market Share & Forecast
6.5.9.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.10. Austria Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.10.1. Market Size & Forecast
6.5.10.1.1. By Value & Volume
6.5.10.2. Market Share & Forecast
6.5.10.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)

7. Market Dynamics
7.1. Drivers
7.2. Challenges

8. Market Trends & Developments

9. Porter's Five Forces Analysis
9.1. Bargaining Power of Suppliers
9.2. Bargaining Power of Consumers
9.3. Threat of New Suppliers
9.4. Threat of Substitute
9.5. Competitive Rivalry

10. Competitive Landscape
10.1. Competition Outlook
10.2. Company Profiles
10.2.1. Basic Financial Details (Revenue, Gross Profit, Net Profit)
10.2.2. Sales Value and Volume of Product of Interest
10.2.3. Key Strategies
10.2.3.1. New Products Launches
10.2.3.2. Product Development Plan
10.2.3.3. Expansion Plan
10.2.4. Supply Chain Analysis
10.2.5. Business Distribution
10.2.6. SWOT Analysis

11. Timelines from Drug Development to Commercial Launch

12. Strategic Recommendations

List of Figures:
Figure 1: Europe Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F (USD Million)
Figure 2: Europe Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 4: Europe Diabetic Population Share, 2017
Figure 3: Germany Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 4: Germany Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 5: United Kingdom Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 6: United Kingdom Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 7: France Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 8: France Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 9: Italy Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 10: Italy Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 11: Spain Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 12: Spain Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 13: Russia Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 14: Russia Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 15: Turkey Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 16: Turkey Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 17: Poland Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 18: Poland Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 19: The Netherlands Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 20: The Netherlands Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 21: Austria Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 22: Austria Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 23: Europe Biosimilar Insulin Glargine and Lispro Pricing Analysis, 2014-2024F
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Sanofi S.A
  • Biocon Limited
  • Novo Nordisk A/S
  • Wockhardt Ltd
  • Eli Lily and Company
  • Geropharm LLC
  • Merck & Co.
  • Sandoz
Note: Product cover images may vary from those shown
Adroll
adroll